ACRS..Eskata approval likely next week guys , 10 months review timeline like in USA so approval should come next week Price $1.17 ...Market cap $48 Million ...Cash $115Million ...Book Value $3.30 ...Cash per Share $2.79 Cipher Pharmaceuticals Announces A-101 40% Topical Solution Accepted for Review by Health Canada https://cipher.investorroom.com/201...Solution-Accepted-for-Review-by-Health-Canada Dec. 18, 2018 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:CPH) today announced that its New Drug Submission ("NDS") for A-101 40% topical solution ("A-101 40%") for the treatment of raised seborrheic keratoses ("SKs") has been accepted for review by Health Canada. Cipher acquired the exclusive Canadian rights to distribute and commercialize A-101 40% from Aclaris Therapeutics, Inc. (NASDAQ:ACRS) ("Aclaris") in April 2018. A-101 40% is a U.S. Food and Drug Administration ("FDA")-approved product indicated for the treatment of raised SKs, which are commonly occurring non-cancerous skin growths that affect more than 9 million Canadian adults and can be an aesthetic skin concern. A-101 40% was approved by the FDA in December 2017 and is marketed by Aclaris in the U.S. under the tradename Eskata™.
ACRS = RALLLYYYYYYYYYYYYYY in after hour on good news Price $1.40 // Market Cap $56 Million Cash now AT $145 Milllion ,,LOVE IT Aclaris Therapeutics Announces Divestiture of RHOFADE® https://www.globenewswire.com/news-...peutics-Announces-Divestiture-of-RHOFADE.html
William Blair sees 'significant value disconnect' in Aclaris Therapeutics William Blair analyst Tim Lugo maintains an Outperform rating on Aclaris Therapeutics after the company announced the divestiture of worldwide rights for Rhofade to EPI Health for up to $55M. The analyst says the deal value compares well with his previously estimated net present value for the Rhofade program of $65M. The divestiture is a first step in management extracting value from its commercial portfolio as the company has signaled additional partnerships and divestitures, Lugo tells investors in a research note. He continues to see a "significant value disconnect" with Aclaris shares trading at less than half of cash. The analyst sees "some promising early-stage assets, and near-term potential for strategic partnerships." Read more at: https://thefly.com/landingPageNews.php?id=2974505
